18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CT

References

• Gordon L, Harrington D, Anderson J, et al. Comparison of a second-generation combination chemotherapy regimen (m-BACOP) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1342–1349
   PubMed Web of Science ®Google Scholar
• Fisher R I, Gaynor E R, Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Linch D C, Vaughan Hudson B, Hancock B W, et al. A randomised comparison of a third-generation regimen (PACE-BOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report. B J Cancer 1996; 74: 318–322
   PubMed Web of Science ®Google Scholar
• Verdonck L F, Dekker A W, deGast G C, et al. Salvage therapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP. J Clin Oncol 1992; 10: 1949–54
   PubMed Web of Science ®Google Scholar
• Mills W, Chopra R, McMillan A, et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588–95
   PubMed Web of Science ®Google Scholar
• Thompson W M. Radiologic Clinics of North America: Staging Neoplasms. WB Saunders, Philadelphia 1994; Vol II, No I
   Google Scholar
• Lewis E, Bernardino M E, Salvador P G, et al. Post-therapy CT-detected masses in lymphoma patients: Is it viable tissue?. J Comp Ass Tom 1982; 792–5
   PubMed Web of Science ®Google Scholar
• Canellos G P. Residual masses in lymphoma may not be residual disease. J Clin Oncol 1988; 6: 931–3
   PubMed Web of Science ®Google Scholar
• Surbone A, Longo D L, De Vita V T, Jr, et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combonation chemotherapy: significance and management. J Clin Oncol 1988; 6: 1832–7
   PubMed Web of Science ®Google Scholar
• Kaplan W, Jochelson M, Herman T, et al. Gallium-67 imaging: a predictor of residual tumour viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol 1990; 8: 1966–1970
   PubMed Web of Science ®Google Scholar
• Front D, Israel O. The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Semin Nucl Med 1995; 25: 60–71
   PubMed Web of Science ®Google Scholar
• Janicek M, Kaplan W, Neuberg D, et al. Early restaging Gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997; 15: 1631–1637
   PubMed Web of Science ®Google Scholar
• Okada J, Yoshikawa K, Imaseki K, et al. The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis. J Nucl Med 1991; 32: 686–691
   PubMed Web of Science ®Google Scholar
• Newman J S, Francis I R., Kaminski M S, Wahl R L. imaging of lymphoma with PET with 2-(F-18]-Fluoro-2-deoxy-D-glucose: Correlation with CT. Radiology 1994; 190: 111–116
   PubMed Web of Science ®Google Scholar
• Okada J, Oonishi H, Yoshikawa K, et al. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 1994; 8: 187–191
   PubMedGoogle Scholar
• Bangerter M, Kocher F, Binder T, et al. Total body positron emission tomography (PET) for staging and follow-up of lymphoma. Proc ASCO 1995; 387
   Google Scholar
• Hoh C K, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38: 343–348
   PubMed Web of Science ®Google Scholar
• de Wit M, Bumann D, Beyer W., et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997; 8(suppl. 1)57–60
   PubMed Web of Science ®Google Scholar
• Bangerter M, Moog F, Hafner M, et al. Whole body FDG-PET for staging and post-treatment follow-up of residual masses in patients with newly diagnosed Hodgkin's disease. Proc ASCO 1997; 26
   Google Scholar
• Mikhaeel N G, Ahern V, Barrington S, Timothy A R. Post-treatment remission assessment in lymphoma using FDG-PET scanning. Br J Cancer 1997; 76(suppl 1)32
   Google Scholar
• Jerusalem G, Beguin Y, Fassotte M-F, et al. Whole-body FDG-PET post-treatment evaluation in Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) has higher diagnostic and prognostic value than classical CT scan imaging. Blood 1997; 90(suppl 1)336a
   Google Scholar
• Stumpe K D, Urbinelli M, Steinert H C, et al. Whole body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998; 25: 721–8
   PubMedGoogle Scholar
• Moog F, Bangerter M, Diederichs C, et al. Detection of extranodal malignant lymphoma with positron-emission-tomography using Fluorine-18-fluorodeoxy-glucose (FDG-PET): Comparison with computed tomography (CT). Radiology 1998; 206: 475–481
   PubMed Web of Science ®Google Scholar
• Mikhaeel N G, Timothy A R, Hain S, et al. 18-FDG-PET for assessment of residual masses on CT after treatment of lymphomas. Ann Oncol 2000; 11(1 Suppl)147–50
   PubMed Web of Science ®Google Scholar
• Romer W, Hanauske A, Ziegler S, et al. Positron Emission Tomography in Non-Hodgkin's Lymphoma: Assessment of Chemotherapy With Fluorodeoxyglucose. Blood 1998; 91: 4464–4471
   PubMed Web of Science ®Google Scholar
• Bland M. An introduction to medical statistics., second edition. Oxford University Press, Oxford, New York, Tokyo 1995; 225
   Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1985; 53: 457–81
   Google Scholar
• Shipp M A, Harrington D P, Anderson J R, et al. A predictive model for aggressive Non-Hodgkin's Lymphoma. The International Non-Hodgkin's Lymphoma prognostic factors project. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Jones D N, McCowage G B, Sostman H D, et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med 1996; 37: 931
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulou-Strauss A, Strauss L G, Goldschmidt H, et al. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995; 22: 434
   PubMedGoogle Scholar
• Hoekstra O S, Ossenkoppele G J, Golding R, et al. Early treatment response in malignant lymphoma, as determined by planner tluorine-1 8-fluorodeoxyglucose scintigraphy. J Nucl Med 1993; 34: 1706
   PubMed Web of Science ®Google Scholar
• Lodge M A, Lucas J D, Marsden P K, et al. A PET study of 18-FDG uptake in soft tissue masses. Eur J Nucl Med 1999; 26: 12–30
   PubMedGoogle Scholar
• Armitage J, Weisenburger D, Hutchins M, et al. Chemotherapy for diffuse large-cell lymphoma- Rapidly responding patients have more durable remissions. J Clin Oncol 1986; 4: 100–164
   Web of Science ®Google Scholar
• Engelhard M PM, Brittinger G, et al. Prospective multicenter trial for the response- adapted treatment of high-grade malignant non-Hodgkin's lymphomas: Updated results of the COP-BLAM/IMVP 16 protocol with randomized adjuvant radiotherapy. Ann Oncol 1991; 2: 177–180
   PubMed Web of Science ®Google Scholar
• Verdonck L F, van Putten W L, Hagenbeek A, et al. Comparison of CHOP chemotherapy with autologous hone marrow transplatation for slowly responding patients with aggressive non-Hodgkin's lymphomas. N Engl J Med 1995; 332: 1045–51
   PubMed Web of Science ®Google Scholar
• International Commission on Radiological Protection (ICRP). Annals of the ICRP 53. Pergamon Press. 1987; Vol 18, Nos 1–4
   Google Scholar
• Bartold S P, Donohoe K J, Fletcher J W, et al. Procedure guideline for gallium scintigraphy in the evaluation of malignant disease. J Nucl Med 1997; 39: 990
   Web of Science ®Google Scholar